Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,329 | 61 | 95.2% |
| Consulting Fee | $34.96 | 1 | 2.5% |
| Education | $32.48 | 2 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $329.92 | 10 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $124.75 | 1 | $0 (2017) |
| Itamar Medical Inc | $114.62 | 2 | $0 (2022) |
| Philips Electronics North America Corporation | $109.31 | 3 | $0 (2023) |
| Insmed, Inc. | $96.17 | 6 | $0 (2022) |
| GlaxoSmithKline, LLC. | $92.30 | 7 | $0 (2019) |
| Grifols USA, LLC | $56.14 | 3 | $0 (2019) |
| HARMONY BIOSCIENCES LLC | $54.28 | 3 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $52.41 | 3 | $0 (2024) |
| Genentech USA, Inc. | $51.95 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109.90 | 6 | HARMONY BIOSCIENCES LLC ($37.82) |
| 2023 | $64.03 | 4 | Philips Electronics North America Corporation ($18.19) |
| 2022 | $251.71 | 11 | Itamar Medical Inc ($79.66) |
| 2021 | $113.98 | 6 | Insmed, Inc. ($65.36) |
| 2020 | $11.34 | 1 | Genentech USA, Inc. ($11.34) |
| 2019 | $188.10 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($39.75) |
| 2018 | $420.06 | 15 | AstraZeneca Pharmaceuticals LP ($260.81) |
| 2017 | $237.09 | 8 | E.R. Squibb & Sons, L.L.C. ($124.75) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 3 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/21/2018 | Philips Electronics North America Corporation | Respiratoriy Care Undiv (Device) | Food and Beverage | Cash or cash equivalent | $72.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/07/2018 | Sunovion Pharmaceuticals Inc. | Utibron (Drug), Seebri, Lonhala Magnair | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: Respiratory | ||||||
| 02/21/2018 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $10.84 | General |
| 01/19/2018 | Genentech USA, Inc. | Esbriet (Biological) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Immunology | ||||||
| 01/10/2018 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $0.42 | General |
| Category: HFCWO | ||||||
| 01/09/2018 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $10.57 | General |
| Category: HFCWO | ||||||
| 11/15/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2017 | Novartis Pharmaceuticals Corporation | FEVIPIPRANT (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| 08/23/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: RESPIRATORY | ||||||
| 07/25/2017 | Grifols USA, LLC | Prolastin-C (Biological) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Pulmonology | ||||||
| 06/13/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $124.75 | General |
| Category: Cardiovascular | ||||||
| 05/30/2017 | Gilead Sciences Inc | — | Food and Beverage | In-kind items and services | $14.52 | General |
| 02/28/2017 | Sunovion Pharmaceuticals Inc. | BROVANA (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: RESPIRATORY | ||||||
| 02/23/2017 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 981 | 1,366 | $417,193 | $103,296 |
| 2022 | 15 | 962 | 1,394 | $385,169 | $101,557 |
| 2021 | 20 | 1,204 | 1,795 | $473,823 | $140,162 |
| 2020 | 20 | 1,100 | 1,776 | $464,184 | $140,683 |
All Medicare Procedures & Services
80 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 51 | 135 | $95,175 | $21,096 | 22.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 147 | 357 | $66,750 | $20,845 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 111 | 161 | $44,436 | $14,406 | 32.4% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 174 | 174 | $74,761 | $11,362 | 15.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 82 | $22,058 | $7,205 | 32.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 65 | 65 | $23,400 | $5,858 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 74 | $17,982 | $4,661 | 25.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $18,375 | $4,432 | 24.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 39 | $13,806 | $3,730 | 27.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $8,400 | $2,233 | 26.6% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 20 | 20 | $6,960 | $1,717 | 24.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 35 | 36 | $5,292 | $1,386 | 26.2% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 35 | 36 | $5,148 | $1,328 | 25.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $4,384 | $1,151 | 26.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 35 | 37 | $6,142 | $982.10 | 16.0% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 14 | 14 | $1,330 | $323.05 | 24.3% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 16 | 17 | $1,224 | $211.82 | 17.3% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 15 | 15 | $525.00 | $133.80 | 25.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 17 | 17 | $629.00 | $129.37 | 20.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 16 | 16 | $416.00 | $105.28 | 25.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 145 | 353 | $62,834 | $18,628 | 29.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 55 | 112 | $75,152 | $18,088 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 110 | 170 | $44,710 | $15,078 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 80 | 169 | $43,264 | $12,837 | 29.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 58 | 60 | $30,000 | $8,690 | 29.0% |
About Dr. Sylvia Rael, M.D
Dr. Sylvia Rael, M.D is a Pulmonary Disease healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1386648095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sylvia Rael, M.D has received a total of $1,396 in payments from pharmaceutical and medical device companies, with $109.90 received in 2024. These payments were reported across 64 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,329).
As a Medicare-enrolled provider, Rael has provided services to 4,247 Medicare beneficiaries, totaling 6,331 services with total Medicare billing of $485,699. Data is available for 4 years (2020–2023), covering 80 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Sleep Medicine
- Location Omaha, NE
- Active Since 06/09/2005
- Last Updated 08/22/2016
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1386648095
Products in Payments
- FASENRA (Drug) $155.14
- ELIQUIS (Drug) $124.75
- WatchPAT (Device) $114.62
- Arikayce (Drug) $96.17
- Respiratoriy Care Undiv (Device) $72.81
- NUCALA (Biological) $56.68
- Xolair (Biological) $39.98
- XYWAV (Drug) $38.75
- Prolastin-C Liquid (Biological) $38.50
- WAKIX (Drug) $37.82
- DUPIXENT (Biological) $32.54
- OFEV (Drug) $28.06
- Adempas (Drug) $27.52
- FASENRA (Biological) $26.92
- TRELEGY ELLIPTA (Drug) $24.17
- BROVANA (Drug) $23.81
- INSPIRE (Device) $23.47
- SMARTVEST (Device) $20.78
- ORENITRAM (Drug) $18.60
- (4219) Wisp (Device) $18.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Omaha
Dr. Douglas Moore, M.d, M.D
Pulmonary Disease — Payments: $44,617
Stephen Rennard, Md, MD
Pulmonary Disease — Payments: $32,530
Austin Thompson, Md, MD
Pulmonary Disease — Payments: $18,317
Patrick Meyers, M.d, M.D
Pulmonary Disease — Payments: $12,153
Lee Morrow, M.d, M.D
Pulmonary Disease — Payments: $10,157
Palvannanathan Ganesan, M.d, M.D
Pulmonary Disease — Payments: $8,217